| review article | Q7318358 |
| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1085600609 |
| P356 | DOI | 10.1186/S13023-017-0652-Y |
| P932 | PMC publication ID | 5445371 |
| P698 | PubMed publication ID | 28545481 |
| P50 | author | Cara A Timpani | Q86409870 |
| Emma Rybalka | Q52152129 | ||
| P2093 | author name string | Alan Hayes | |
| P2860 | cites work | Decreased total nitric oxide production in patients with duchenne muscular dystrophy. | Q52553786 |
| Nitric oxide activates or inhibits skeletal muscle ryanodine receptors depending on its concentration, membrane potential and ligand binding. | Q53917676 | ||
| Dietary nitrate supplementation reduces the O2 cost of low-intensity exercise and enhances tolerance to high-intensity exercise in humans | Q56864000 | ||
| Nitric oxide donor and non steroidal anti inflammatory drugs as a therapy for muscular dystrophies: Evidence from a safety study with pilot efficacy measures in adult dystrophic patients | Q59484926 | ||
| Effect of sildenafil on skeletal and cardiac muscle in Becker muscular dystrophy | Q60772304 | ||
| Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy | Q24307833 | ||
| Nitric oxide and peroxynitrite in health and disease | Q24645400 | ||
| Sildenafil and cardiomyocyte-specific cGMP signaling prevent cardiomyopathic changes associated with dystrophin deficiency | Q24655371 | ||
| Nitric oxide synthases, S-nitrosylation and cardiovascular health: from molecular mechanisms to therapeutic opportunities (review) | Q26823520 | ||
| Skeletal muscle nitric oxide signaling and exercise: a focus on glucose metabolism | Q26995484 | ||
| Citrulline a more suitable substrate than arginine to restore NO production and the microcirculation during endotoxemia | Q27302422 | ||
| Primary role of functional ischemia, quantitative evidence for the two-hit mechanism, and phosphodiesterase-5 inhibitor therapy in mouse muscular dystrophy | Q27302822 | ||
| The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein | Q28118471 | ||
| Population frequencies of inherited neuromuscular diseases—A world survey | Q28266298 | ||
| Mechanisms of nitrite bioactivation | Q28384653 | ||
| Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy | Q28474542 | ||
| Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy | Q28484851 | ||
| Dystrophin: the protein product of the Duchenne muscular dystrophy locus | Q29618077 | ||
| Attempting to Compensate for Reduced Neuronal Nitric Oxide Synthase Protein with Nitrate Supplementation Cannot Overcome Metabolic Dysfunction but Rather Has Detrimental Effects in Dystrophin-Deficient mdx Muscle | Q33586004 | ||
| Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy | Q33649312 | ||
| Drug screening in a zebrafish model of Duchenne muscular dystrophy. | Q33845739 | ||
| Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions | Q33860484 | ||
| The clinical pharmacology of L-arginine | Q33939368 | ||
| PDE5 inhibition alleviates functional muscle ischemia in boys with Duchenne muscular dystrophy | Q33987140 | ||
| Neuronal nitric oxide synthase-rescue of dystrophin/utrophin double knockout mice does not require nNOS localization to the cell membrane | Q34049251 | ||
| Dietary inorganic nitrate reverses features of metabolic syndrome in endothelial nitric oxide synthase-deficient mice | Q34199764 | ||
| Sildenafil reverses cardiac dysfunction in the mdx mouse model of Duchenne muscular dystrophy. | Q34279254 | ||
| Sildenafil does not improve cardiomyopathy in Duchenne/Becker muscular dystrophy. | Q34315276 | ||
| Evaluation of bacterial nitrate reduction in the human oral cavity | Q34391222 | ||
| Dietary nitrate increases arginine availability and protects mitochondrial complex I and energetics in the hypoxic rat heart. | Q34619501 | ||
| Potential oxyradical damage and energy status in individual muscle fibres from degenerating muscle diseases | Q68045270 | ||
| Effect of Duchenne muscular dystrophy on enzymes of energy metabolism in individual muscle fibers | Q69075882 | ||
| EMG computerized analysis of localized fatigue in Duchenne muscular dystrophy | Q70197822 | ||
| Decreased insulin receptors but normal glucose metabolism in Duchenne muscular dystrophy | Q70298216 | ||
| Immunohistochemical study of calpain and its endogenous inhibitor in the skeletal muscle of muscular dystrophy | Q71905306 | ||
| The serum nitric oxide levels in patients with Duchenne muscular dystrophy | Q73801088 | ||
| Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro | Q74607760 | ||
| The effect of age and temperature on mdx muscle fatigue | Q74759953 | ||
| Survival in Duchenne muscular dystrophy: improvements in life expectancy since 1967 and the impact of home nocturnal ventilation | Q78616932 | ||
| Cyclic nucleotide phosphodiesterase isozymes expressed in mouse skeletal muscle | Q78878396 | ||
| Dietary nitrate supplementation reduces the O2 cost of walking and running: a placebo-controlled study | Q82431001 | ||
| Dissecting the signaling and mechanical functions of the dystrophin-glycoprotein complex | Q82995100 | ||
| Acute dietary nitrate supplementation improves cycling time trial performance | Q83799502 | ||
| Dietary nitrate supplementation improves rowing performance in well-trained rowers | Q84402341 | ||
| No improvement in endurance performance after a single dose of beetroot juice | Q84581034 | ||
| The effect of nitrate supplementation on muscle contraction in healthy adults | Q86935044 | ||
| Nitrate supplementation enhances the contractile properties of human skeletal muscle | Q87556092 | ||
| Effect of dietary nitrate supplementation on tolerance to supramaximal intensity intermittent exercise | Q50444009 | ||
| Beetroot juice supplementation reduces whole body oxygen consumption but does not improve indices of mitochondrial efficiency in human skeletal muscle. | Q51584583 | ||
| Evidence for a myogenic stem cell that is exhausted in dystrophic muscle. | Q52168124 | ||
| Does utrophin expression in muscles of mdx mice during postnatal development functionally compensate for dystrophin deficiency? | Q52217515 | ||
| Interactions between bioenergetics and mitochondrial biogenesis | Q41015290 | ||
| Sildenafil reduces respiratory muscle weakness and fibrosis in the mdx mouse model of Duchenne muscular dystrophy | Q41031903 | ||
| Nuclear recruitment of neuronal nitric-oxide synthase by α-syntrophin is crucial for the induction of mitochondrial biogenesis | Q41848388 | ||
| Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure | Q42507993 | ||
| Dietary nitrate increases tetanic [Ca2+]i and contractile force in mouse fast-twitch muscle | Q42717596 | ||
| Ibuprofen plus isosorbide dinitrate treatment in the mdx mice ameliorates dystrophic heart structure. | Q43697562 | ||
| Creatine supplementation reduces skeletal muscle degeneration and enhances mitochondrial function in mdx mice | Q43818941 | ||
| A quantitative study of bioenergetics in skeletal muscle lacking utrophin and dystrophin. | Q43860533 | ||
| Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins | Q44807148 | ||
| Defects in neuromuscular junction structure in dystrophic muscle are corrected by expression of a NOS transgene in dystrophin-deficient muscles, but not in muscles lacking alpha- and beta1-syntrophins | Q44967389 | ||
| Nitrate supplementation's improvement of 10-km time-trial performance in trained cyclists | Q44988842 | ||
| Mutation in dystrophin-encoding gene affects energy metabolism in mouse myoblasts | Q45242416 | ||
| Neuronal nitric oxide synthase isoforms alpha and mu are closely related calpain-sensitive proteins. | Q45937201 | ||
| Sodium nitrate alleviates functional muscle ischaemia in patients with Becker muscular dystrophy | Q46088505 | ||
| Cardiomyopathy in dystrophin-deficient hearts is prevented by expression of a neuronal nitric oxide synthase transgene in the myocardium | Q46285519 | ||
| Expression of a muscle-specific, nitric oxide synthase transgene prevents muscle membrane injury and reduces muscle inflammation during modified muscle use in mice | Q46485498 | ||
| Systemic administration of L-arginine benefits mdx skeletal muscle function | Q46664538 | ||
| L-arginine improves dystrophic phenotype in mdx mice | Q46682624 | ||
| Persistent and improved functional gain in mdx dystrophic mice after treatment with L-arginine and deflazacort | Q46933224 | ||
| Increased caveolin-3 levels in mdx mouse muscles | Q47763919 | ||
| A nitrate ester of sedative alkyl alcohol improves muscle function and structure in a murine model of Duchenne muscular dystrophy | Q47836273 | ||
| Impaired mitochondrial oxidative phosphorylation in skeletal muscle of the dystrophin-deficient mdx mouse | Q47878704 | ||
| Revisiting the dystrophin-ATP connection: How half a century of research still implicates mitochondrial dysfunction in Duchenne Muscular Dystrophy aetiology | Q47966217 | ||
| Dietary nitrate supplementation in COPD: an acute, double-blind, randomized, placebo-controlled, crossover trial | Q48005929 | ||
| Arginine butyrate: a therapeutic candidate for Duchenne muscular dystrophy. | Q48153388 | ||
| Nitric oxide donors improve prednisone effects on muscular dystrophy in the mdx mouse diaphragm | Q50283542 | ||
| Dietary inorganic nitrate improves mitochondrial efficiency in humans. | Q34626699 | ||
| Defects in mitochondrial ATP synthesis in dystrophin-deficient mdx skeletal muscles may be caused by complex I insufficiency. | Q34776381 | ||
| Food sources of nitrates and nitrites: the physiologic context for potential health benefits | Q34980790 | ||
| Dystrophic muscle improvement in zebrafish via increased heme oxygenase signaling. | Q35043351 | ||
| Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease | Q35057110 | ||
| Nitric oxide signalling pathway in Duchenne muscular dystrophy mice: up-regulation of L-arginine transporters | Q35195095 | ||
| Dietary nitrate supplementation improves exercise performance and decreases blood pressure in COPD patients | Q35542901 | ||
| Nitric oxide release combined with nonsteroidal antiinflammatory activity prevents muscular dystrophy pathology and enhances stem cell therapy | Q35575973 | ||
| Novel mini-dystrophin gene dual adeno-associated virus vectors restore neuronal nitric oxide synthase expression at the sarcolemma | Q35678425 | ||
| Nitrate enhances skeletal muscle fatty acid oxidation via a nitric oxide-cGMP-PPAR-mediated mechanism | Q35875662 | ||
| Improved Muscle Function in Duchenne Muscular Dystrophy through L-Arginine and Metformin: An Investigator-Initiated, Open-Label, Single-Center, Proof-Of-Concept-Study. | Q35901453 | ||
| Naproxcinod shows significant advantages over naproxen in the mdx model of Duchenne Muscular Dystrophy | Q35986842 | ||
| Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study | Q35991086 | ||
| A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice | Q36294012 | ||
| Deficient ryanodine receptor S-nitrosylation increases sarcoplasmic reticulum calcium leak and arrhythmogenesis in cardiomyocytes | Q36300139 | ||
| Sarcolemmal targeting of nNOSμ improves contractile function of mdx muscle | Q36402599 | ||
| Detection of deletions spanning the Duchenne muscular dystrophy locus using a tightly linked DNA segment | Q36423793 | ||
| Defects in mitochondrial localization and ATP synthesis in the mdx mouse model of Duchenne muscular dystrophy are not alleviated by PDE5 inhibition | Q36467072 | ||
| L-arginine decreases inflammation and modulates the nuclear factor-kappaB/matrix metalloproteinase cascade in mdx muscle fibers | Q36691055 | ||
| Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle | Q36760419 | ||
| Sarcolemma-localized nNOS is required to maintain activity after mild exercise | Q36987100 | ||
| The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics | Q37048314 | ||
| Dystrophins carrying spectrin-like repeats 16 and 17 anchor nNOS to the sarcolemma and enhance exercise performance in a mouse model of muscular dystrophy. | Q37111368 | ||
| Dual AAV therapy ameliorates exercise-induced muscle injury and functional ischemia in murine models of Duchenne muscular dystrophy | Q37111962 | ||
| Treatment with L-citrulline and metformin in Duchenne muscular dystrophy: study protocol for a single-centre, randomised, placebo-controlled trial | Q37150891 | ||
| Tadalafil Treatment Delays the Onset of Cardiomyopathy in Dystrophin-Deficient Hearts | Q37240478 | ||
| Loss of positive allosteric interactions between neuronal nitric oxide synthase and phosphofructokinase contributes to defects in glycolysis and increased fatigability in muscular dystrophy | Q37312499 | ||
| Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy | Q37387484 | ||
| Cardiorespiratory function associated with dietary nitrate supplementation | Q37541277 | ||
| Tadalafil alleviates muscle ischemia in patients with Becker muscular dystrophy. | Q37604365 | ||
| New Pharmacological Strategies to Increase cGMP. | Q38608909 | ||
| Low doses of arginine butyrate derivatives improve dystrophic phenotype and restore membrane integrity in DMD models. | Q39017870 | ||
| A biochemical study of certain skeletal muscle constituents in human progressive muscular dystrophy | Q40330875 | ||
| Nitrate, nitrite and N-nitroso compounds. | Q40600062 | ||
| Pathways Implicated in Tadalafil Amelioration of Duchenne Muscular Dystrophy. | Q40813682 | ||
| Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy | Q40910686 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | bioavailability | Q461809 |
| Duchenne muscular dystrophy | Q1648484 | ||
| mechanism of action | Q3271540 | ||
| enzyme | Q8047 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 100 | |
| P577 | publication date | 2017-05-25 | |
| P1433 | published in | Orphanet Journal of Rare Diseases | Q15756117 |
| P1476 | title | Therapeutic strategies to address neuronal nitric oxide synthase deficiency and the loss of nitric oxide bioavailability in Duchenne Muscular Dystrophy | |
| P478 | volume | 12 |
| Q52564618 | Combined Therapies for Duchenne Muscular Dystrophy to Optimize Treatment Efficacy. |
| Q91811820 | Metabolic Alterations in Cardiomyocytes of Patients with Duchenne and Becker Muscular Dystrophies |
| Q55515149 | Skeletal Muscle Metabolism in Duchenne and Becker Muscular Dystrophy-Implications for Therapies. |
| Q92637631 | The Role of Macrophage Migration Inhibitory Factor in Alzheimer's Disease: Conventionally Pathogenetic or Unconventionally Protective? |
Search more.